Enveric Biosciences (ENVB) Interest Expenses (2013 - 2025)
Enveric Biosciences (ENVB) posted Interest Expenses of $32892.0 for Q4 2025, up 4.83% sequentially from $31376.0 in Q4 2024, and up 4.83% YoY from $31376.0 in Q4 2024.
Enveric Biosciences (ENVB) Interest Expenses (2013 - 2025) Analysis & Trends
Enveric Biosciences has reported Interest Expenses for 13 years, with the latest figure at $32892.0 in Q4 2025.
- Quarterly Interest Expenses rose 4.83% year-over-year to $32892.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $32892.0 (up 4.83% YoY) and the FY2025 annual result came in at $32892.0, down 82.69% from the prior year.
- Interest Expenses improved to $32892.0 in Q4 2025 per ENVB's latest filing, from $31376.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $12.8 million in Q4 2023 and troughed at $11.0 in Q1 2023.
- A 5-year average of $1.2 million and a median of $18250.5 in 2021 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses tumbled 99.96% in 2022, then surged 9509348.15% in 2023.
- Over 5 years, Interest Expenses stood at $5125.0 in 2021, then plunged by 97.37% to $135.0 in 2022, then soared by 9509348.15% to $12.8 million in 2023, then slumped by 99.76% to $31376.0 in 2024, then rose by 4.83% to $32892.0 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $32892.0, $31376.0, and $12.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Enveric Biosciences | 5.42 Mn | -2.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32,892.00 |
| Dec 31, 2025 | 32,892.00 |
| Dec 31, 2024 | 31,376.00 |
| Dec 31, 2024 | 31,376.00 |
| Dec 31, 2023 | 12.84 Mn |
| Dec 31, 2023 | 12.84 Mn |
| Mar 31, 2023 | 11.00 |
| Mar 31, 2023 | 11.00 |
| Dec 31, 2022 | 135.00 |
| Dec 31, 2022 | 135.00 |
| Sep 30, 2022 | 308.00 |
| Sep 30, 2022 | 308.00 |
| Jun 30, 2022 | 668.00 |
| Jun 30, 2022 | 668.00 |
| Mar 31, 2022 | 4,138.00 |
| Mar 31, 2022 | 4,138.00 |
| Dec 31, 2021 | 5,125.00 |
| Dec 31, 2021 | 5,125.00 |
| Sep 30, 2021 | 730,438.00 |
| Sep 30, 2021 | 730,438.00 |